Inhaled Corticosteroids and Respiratory Infections in Children With Asthma: A Meta-analysis.
Inhaled corticosteroids (ICS) are associated with an increased risk of pneumonia in adult patients with chronic obstructive pulmonary disease. To assess the association between ICS use and risk of pneumonia and other respiratory infections in children with asthma. We searched PubMed from inception until May 2015. We also searched clinicaltrials.gov and databases of pharmaceutical manufacturers. We selected randomized trials that compared ICS with placebo for at least 4 weeks in children with asthma. We included 39 trials, of which 31 trials with 11 615 patients contributed data to meta-analyses. The incidence of pneumonia was 0.58% (44/7465) in the ICS group and 1.51% (63/4150) in the placebo group. The meta-analysis of 9 trials that revealed at least 1 event of pneumonia revealed a reduced risk of pneumonia in patients taking ICS (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.44 to 0.94). Using risk difference as effect measure, the meta-analysis including all 31 trials revealed no significant difference in the risk of pneumonia between the ICS and placebo groups (risk difference: -0.1%; 95% CI: -0.3% to 0.2%). No significant association was found between ICS and risk of pharyngitis (RR: 1.01; 95% CI: 0.87 to 1.18), otitis media (RR: 1.07; 95% CI: 0.83 to 1.37), and sinusitis (RR: 0.89; 95% CI: 0.76 to 1.05). Lack of clearly defined criteria for respiratory infections and possible publication bias. Regular use of ICS may not increase the risk of pneumonia or other respiratory infections in children with asthma.